Mirum Pharmaceuticals price target raised to $175 from $150 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $175 from $150 and keeps a Buy rating on the shares after the company reported positive topline data from the Phase 2b VISTAS study of volixibat in patients with cholestatic pruritus in primary sclerosing cholangitis. Beyond PSC, the firm views VISTAS towline results as “a meaningful de-risking event” for the VANTAGE Phase 2b study evaluating volixibat in primary biliary cholangitis, the analyst tells investors.